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ABSTRACT
Objectives: We measured health utility (HU) in Thai HIV/AIDS patients
using visual analog scale (VAS), EuroQOL (EQ-5D), and standard gamble
(SG), determine the relationships between these HU measures and health-
related quality of life (HRQOL) measures of HIV and patient character-
istics, and assess the feasibility of the HU methods.
Methods: A sample of 120 HIV/AIDS patients was identiﬁed at Bamras-
naradura Infectious Disease Institute, Thailand, during September to
December, 2004. Face-to-face interviews included VAS, SG, and EQ-5D,
HRQOL assessment using the Thai abbreviated version of the World
Health Organization quality of life (WHOQOL-BREF THAI) and HIV-
related symptom instruments, questions about ease of understanding
HU approaches and sociodemographic items. Data were analyzed with
repeated-measures ANOVA, followed by Dunn–Bonferroni t-test, intrac-
lass coefﬁcients (ICC), Spearman’s rank correlation, and multiple linear
regressions.
Results: The mean (95% conﬁdence interval) HUs were as follows: VAS,
0.79 (0.76–0.82); EQ-5D, 0.80 (0.77–0.84); and SG, 0.65 (0.60–0.70). A
signiﬁcant difference in HU by method was found (P < 0.001). Agreement
by ICC was 0.71 for VAS versus EQ-5D, 0.41 for VAS versus SG, and 0.38
for EQ-5D and SG. The regression models showed that WHOQOL-BREF
THAI, frequency of HIV symptoms, and patient characteristics could
explain approximately 50% of the variation in the VAS and the EQ-5D
and 20% in the SG2. Among these three HU methods, the SG was the most
difﬁcult task.
Conclusion: VAS, EQ-5D and SG yielded different HUs for this sample.
VAS and EQ-5D showed stronger construct validity with other health
measures than SG. From a feasibility perspective, the SG was the least
satisfactory of the three approaches.
Keywords: EQ-5D, health utility, HIV/AIDS, standard gamble, visual
analog scale.
Introduction
HIV infection and the AIDS epidemic have caused a great eco-
nomic burden to the Thai society since 1984. From 1984 to
2005, the cumulative number of Thai persons who have con-
tracted HIV/AIDS was 1.09 million, whereas in 2005 the total
Thai population was about 64 million [1]. Half of these patients
had died by 2005, and more than 90% of these deaths occurred
in people aged 20 to 44 years. HIV/AIDS has a negative impact
not only on patients’ survival but also on their health-related
quality of life (HRQOL), which is not captured by conventional
and biological clinical measures. HRQOL assessment has there-
fore been extremely important for understanding the impact of
diseases and treatments on the lives of patients with HIV/AIDS.
Because the health-care budget is constrained, economic
evaluations of health-care interventions are needed. An impor-
tant problem in economic evaluation, however, is how to incor-
porate HRQOL data into the analysis. A common approach to
measuring HRQOL is to employ generic and disease-speciﬁc
health status instruments [2,3]. The generic instrument can result
in a single outcome score (health index) or a proﬁle of scores
(health proﬁle). The index and the proﬁle represent the two
approaches to HRQOL assessment: the health utility (HU)
approach and the psychometric approach. The HU approach can
incorporate HRQOL into cost-effectiveness analysis or cost-
utility analysis (CUA) whose commonly used outcomes are
quality-adjusted life years (QALYs) gained [4,5]. The QALY is a
measure of life expectancy weighed by an HU score that is
usually between 0 (death) and 1 (full health).
Unfortunately, even though Thailand has many HIV-infected
patients, no HU data for HIV/AIDS patients were available.
Possible HU assessment methods include: 1) direct methods such
as visual analogue scale (VAS), time trade-off (TTO), and stan-
dard gamble (SG); and 2) indirect methods such as quality of
well-being (QWB), HU Index (HUI), and EuroQOL (EQ-5D) [5].
We did not know which HU assessment methods would work
best with Thai people. Thus, we proposed to measure HU in
HIV/AIDS patients in Thailand using VAS, EQ-5D, and SG, and
to determine the relationships between these HU measures and
HRQOLmeasures, HIV indicators, and patient characteristics. A
second objective was to evaluate the feasibility of HU assessment
in Thai HIV patients. VAS, EQ-5D, and SG were chosen for this
study for the following reasons: the VAS is typically the least
difﬁcult direct HU method to administer; the EQ-5D is a brief
indirect HU measure; and the SG is original HU method based on
the utility theory of decision-making under uncertainty proposed
by von Neumann and Morgenstern [6]. TTO, one of the most
commonly used utility methods, was not selected because the
question of this method may intimidate HIV/AIDS patients
whose lives were suffering. A number of studies described that
the TTO method is intrusive to patients or makes no sense to
them [7,8]. The scoring function of EQ-5D is, however, based on
the TTO method. As for other indirect measured utility methods
such as QWB and HUI, they are time-consuming to administer,
thus causing respondent burden.
Methods
Patient Sample and Procedure
A sample of 120 outpatients living with HIV/AIDS was identiﬁed
at Bamrasnaradura Infectious Disease Institute, the specialized
hospital for treating HIV infection, between September 2 and
December 3, 2004. The HIV/AIDS patients were selected by a
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physician or nurses based on inclusion criteria. Patients who
were eligible for the study were at least 18 years old, able to
understand the Thai language, and with no cognitive impair-
ments. In a private interview room the patient was told about the
details of the study by an investigator. If the patient gave
informed consent, the investigator proceeded with the study
assessment and administered the study questionnaire as a face-
to-face interview. Each of the patients received a stipend of 100
Bahts (~US$2.50).
The interview included HU measured with VAS, SG, and
EQ-5D ordered randomly using a block randomization tech-
nique. HRQOL was assessed using the the Thai abbreviated
version of the World Health Organization quality of life
(WHOQOL-BREF THAI) and HIV-related symptom instru-
ments. The patients were asked to rate their ease of understand-
ing each HU approach, sociodemographic data and their CD4
level. Each interview took approximately 1 hour. This study was
approved by both the University of Minnesota Institutional
Review Board (IRB) and the Ethical Committee of Bamrasnara-
dura Infectious Disease Institute. The study, however, was not
permitted by the University of Minnesota IRB to review the
patients’ medical records. The patients’ clinical HIV stages and
CD4 levels were not known. Therefore, self-reported CD4 levels
were used to categorize their HIV stages. Based on the classiﬁ-
cation system of the Center of Disease Control [9], people
infected with HIV were categorized according to CD4 cells count
as follows: 1) category 1: greater than or equal to 500 cells/mL; 2)
category 2: 200 to 499 cells/mL; and 3) category 3: less than 200
cells/mL. For comparison with other studies, in this study the
categories 1, 2, and 3 were assumed to be equivalent to the
clinical HIV stages including asymptomatic HIV infection, symp-
tomatic HIV infection, and AIDS, respectively.
Instruments
Generic and disease-speciﬁc HRQOL questionnaires used in this
study were as follows:
WHOQOL-BREF THAI. The World Health Organization
developed a generic cross-cultural quality of life instrument
called WHOQOL-100 in 15 countries including Thailand [10].
The WHOQOL is based on a clear deﬁnition of quality of life
that includes physical, psychological, social, and environmental
domains. WHOQOL-BREF is the abbreviated version of the
WHOQOL instrument [11]. It contains 26 items, including 24
items for four domains (physical, psychological, social, and envi-
ronmental), one item for general health, and one item for overall
QOL. There are seven items in the physical domain (items 2, 3,
4, 10, 11, 12, 24), six items in the psychological domain (items 5,
6, 7, 8, 9, 23), three items in the social domain (items 13, 14, 25),
and eight items in the environment domain (items 15 to 22). The
WHOQOL-BREF THAI was developed by Mahatnirunkul et al.
[12]. They found that Cronbach’s alpha of the scale was 0.84.
The WHOQOL-BREF THAI had correlation with the
WHOQOL-100 (r = 0.6515, P < 0.01). The WHOQOL-BREF
THAI also showed acceptable reliability and validity in patients
with HIV/AIDS [13]. In the WHOQOL-BREF, the patients were
required to rate their HRQOL in the past 2 weeks. The item
scores ranged from 1 to 5, with a higher score indicating a better
HRQOL. Because the numbers of items were different for each
domain, the domain scores were calculated by multiplying the
average of the scores of all items in the domain by four. Thus, the
domain scores would have the same range, from 4 to 20.
HIV-related symptoms. A list of the 16 symptoms most fre-
quently described in published reports on HIV patients [14–16]
was developed. Two more symptoms were added by an expert on
HIV/AIDS at the Infectious Disease Institute, so there were 18
items in the version used in this study. The patients were asked to
indicate in the past two weeks how frequently they had experi-
enced any of the following symptoms: fever, fatigue, headache,
paresthesia, imbalance, skin problems, sleep disturbance,
memory loss, sadness, cough, diarrhea, nausea, swallowing
difﬁculty, shortness of breath, impaired vision, loss of appetite,
weight loss, and oral thrush. All items were scored on a four-
point scale where 0 = the symptom did not occur in the previous
2 weeks; 1 = occurred 1 to 3 days per week; 2 = occurred 4 to 6
days per week; and 3 = occurs daily, respectively. The score
ranged from 0 to 54 where a higher summary score indicates
greater symptom burden and lower HRQOL.
HU Methods
VAS. The patients were presented with a vertical line with end-
points of “death” at 0 and “perfect health (both physical and
mental health)” at 100. The respondents were asked to mark the
point on the scale that corresponded to their rating of their
current health state. The HU was obtained by dividing the
number marked on the scale by 100.
EQ-5D. The EQ-5D includes ﬁve domains: mobility, self care,
usual activity, pain/discomfort, and anxiety/depression. Each
domain has three levels: no problems, some problems, and major
problems. Patients were asked to select the level that best
described their current health for each domain. The EQ-5D
responses are scored using weights derived from TTO utilities ob-
tained from a random sample of approximately 3000 adult people
in the United Kingdom [17,18]. The resulting score is between the
0.0 (death) and 1.0 (full health).
SG. HIV/AIDS patients were presented with a hypothetical
choice between remaining in their current health state the rest of
their lives (duration not speciﬁed) and taking a risky treatment
that could result in either perfect health or immediate death with
no pain. The subjects were told that if the treatment worked,
their health would change to perfect health like those without
HIV infection. They were also instructed to think about their
current health with HIV/AIDS, the medications and treatments
required to maintain their health and any worries and concerns
about their health. Before the SG interview began, the inter-
viewer asked if they clearly understood the SG method to ensure
patient comprehension of it. The interview was administered
using cards displaying the risk of death and complementary
probability of cure.
The SG used a top-down titration procedure starting with
100% chance of cure, followed by 95% chance of cure until an
indifferent point was found. The chance of cure was presented in
descending order by a 5% from a 100% chance of cure or a 0%
risk of causing death to a 5% chance of cure or a 95% risk of
causing death. The indifferent point was the midpoint between
the chance of cure represented by the highest value the patient
would accept and the next lower value he or she would decline.
For example, if the patient answered yes (accept the risky treat-
ment) down to 80% chance of cure but no (decline it) to 75%,
the utility was calculated as (0.80 + 0.75)/2 = 0.775. The greater
risk of death a patient was willing to take, the lower HU was. If
the patient answered no to all questions (prefer their own current
health to 100% chance of cure), the utility was equal to 1.0. And,
if patient answered yes to all questions (prefer death to their
current health), the utility was considered to be 0.
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It should be noted that the top-down titration approach was
selected over the ping-pong procedure, one of the most widely
used search methods [19], to facilitate patient understanding,
administration, and scoring because the ping-pong technique
yielded inconsistent results of half of our pilot sample (n = 20).
This ping-pong technique also caused more ﬂoor effects of the SG
method in this sample even though it should preclude anchoring
bias.
Sociodemographic Data
Data on age, sex, income, education, years after HIV diagnosis,
CD4 cell counts, and antiretroviral therapy use were collected at
the conclusion of the HU and HRQOL interview. After complet-
ing the sociodemographic questionnaire, the patients were asked
about how easy it was to understand each HU approach. The
responses were selected from a ﬁve-point scale ranging from
1 = least easy to 5 = easiest. The interview time for each HU
method was also recorded.
Data Analysis
Repeated measures ANOVAs and post hoc comparisons were
performed to determine the differences in means among three HU
methods. Intraclass correlation coefﬁcients (ICCs) were used to
measure agreement between HU methods. Spearman’s rank cor-
relations (rho) and multiple regression equations were employed
to assess the associations between HU scores and the domains of
WHOQOL-BREF THAI, HIV-related symptoms scale, sociode-
mographic, and clinical variables. The feasibility of HU methods
was assessed in terms of rate of refusals, missing data or incom-
plete responses, interviewing time, and ratings of ease of under-
standing. F tests and t tests were used to test for differences in
interview time for the whole sample and by subgroups based on
sex and order of interview of HU methods. The ratings of ease of
understanding were calculated for the whole sample and by
subgroups (sex and order of interview) and compared using
chi-square tests. Spearman’s rank correlation (rho) was used to
assess the associations between interview times, ratings of ease of
understanding, and continuous patient characteristics including
age and level of education. Alpha was set at 0.05 for all statistical




The sample consisted of 120 patients with HIV/AIDS whose
mean age was 36.2  6.7 years. As shown in Table 1, 55.8% of
the sample was male. The average number of years of education
was 10.2  3.8 years. The median monthly income was 5500
Bahts (~$147). The average duration when patients were diag-
nosed with HIV infection was 5.2  4.0 years. Their median
self-reported CD4 count was 180 cells/mL. Most HIV infection
occurred through heterosexual contacts (76.7%). The percentage
of patients taking antiretroviral drugs was 92.5%.
HU
The distribution of HUs measured with VAS, EQ-5D, and SG is
graphed in Figure 1. The VAS and the EQ-5D scores were nega-
tively skewed, indicating that most patients rated their HUs
highly, but a few selected low HUs. Although the shape of the
SG scores looked like a negatively skewed distribution, it
yielded nine zero HU scores. The mean (95% conﬁdence inter-
val [CI]) HU scores were as follows: VAS, 0.79 (0.76–0.82);
EQ-5D, 0.80 (0.77–0.84); and SG, 0.65 (0.60–0.70) (Table 2).
Mean HU scores were signiﬁcantly different across methods
(repeated-measures ANOVA, P < 0.001). Post hoc Bonferroni
tests found that the SG score was signiﬁcantly lower than the
VAS and EQ-5D scores (both P < 0.001). The mean VAS and
EQ-5D scores, however, did not signiﬁcantly differ from each
other (P = 0.36). Medians of the VAS and the EQ-5D were the
same (0.80). The VAS had the smallest range (0.40–1.00),
whereas the EQ-5D and SG had similar large range (0.09–1.00
and 0.00–1.00, respectively). The EQ-5D had the highest
ceiling effects (28.3%), followed by the VAS (10.8%) and the
SG (0.8%), respectively. Floor effects were not found with the
VAS and the EQ-5D but with the SG (7.6%). The VAS and
the EQ-5D had more agreement with each other (ICC of 0.71:
95%CI 0.59–0.80, P < 0.001) than with the SG (ICC of 0.41:
95% CI 0.07–0.61 and ICC of 0.38: 95%CI 0.02–0.60, respec-
tively, P < 0.001; data not shown in Table 2).
Tengs and Lin [20] performed a metaregression using a hier-
archical linear model to derive pooled utilities for HIV/AIDS.
Twenty-ﬁve articles were identiﬁed reporting 74 unique utilities
elicited from 1956 respondents. Compared with Tengs and
Lin’s study, this study showed similar utilities for HIV/AIDS
and was consistent with their patterns where persons with more
advanced stages of HIV infection had lower HU (Table 3). The
HU scores of both studies, however, varied by HU methods.
The HU scores of EQ-5D of this study were pretty close to
pooled utilities elicited from the TTO method of Tengs and
Lin’s study except for the CD4 level < 200 (AIDS). This study,
however, yielded higher VAS scores than VAS scores estimated
from the study of Tengs and Lin (for every stage of HIV infec-
tion). On the other hand, the SG scores of this study were
lower than those of the study of Tengs and Lin except for the
level of CD4 < 200.
Table 1 Characteristics of 120 HIV/AIDS patients
Characteristics Value
Age (year) Mean SD 36.2 6.7
Sex Male 55.8%
Education (year) Mean SD 10.2 3.8
Income Median (25th percentile, 75th percentile) $147 (53, 297)
Years since HIV diagnosis Mean SD 5.2 4.0
CD4 (cells/mL) Median (25th percentile, 75th percentile) 180 (61, 316)
Mode of infection Heterosexual 76.7%
Homosexual 7.5%
Intravenous drug use 7.5%
Tattoos 2.5%
Unknown 5.8%
Antiretroviral drug use Yes 92.5%
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HRQOL
The score distributions of WHOQOL-BREF THAI and fre-
quency of HIV-related symptoms are summarized in Table 4.
The means (95% CI) of the domain scores of WHOQOL-BREF
THAI were 13.9 (13.8–14.4) for the physical domain, 14.0
(13.5–14.5) for the psychological domain, 12.9 (12.4–13.4) for
the social domain, and 13.1 (12.7–13.4) for the environmental
domain. All four domains of WHOQOL-BREF THAI had no
ﬂoor effects and trivial ceiling effects. Cronbach’s alpha ranged
from 0.61 to 0.81 across the four domains. The four domain
scores of this sample were lower than those previously reported
for Taiwanese patients with HIV/AIDS [21]. The mean was 7.7
(95% CI: 6.6–8.8) for the frequency of HIV symptoms. No
ceiling effect but a few ﬂoor effects were observed for the scale
of HIV-related symptoms. The Cronbach’s alpha of the HIV
symptom scale was 0.76, which was more than the acceptable
value of 0.70 [22].
Association between HU and HRQOL
There were signiﬁcant associations between HU (measured using
EQ-5D, VAS, and SG) and generic health status (measured using
the WHOQOL-BREF THAI) (Table 5). The EQ-5D and VAS
had positive signiﬁcant correlations with all four domains of
WHOQOL-BREF THAI (rho: 0.31–0.60; all P < 0.01). The SG,
however, was signiﬁcantly associated with only two domains,
physical and psychological (rho: 0.33–0.34; both P < 0.01).
Higher HU scores were associated with lower frequency of
HIV symptoms (Table 5). Among the three HU approaches, the
EQ-5D was more negatively correlated with the frequency of
HIV symptoms (rho = -0.66; P < 0.01) than VAS (rho = -0.51;
P < 0.01) and SG (rho = -0.26; P < 0.01).
Association between HU and Patient Characteristics
Age and sex were not signiﬁcantly correlated with HUs in this
sample (all methods P > 0.05) (Table 6). The EQ-5D HUs were
positively associated with income (rho = 0.35, P < 0.01) and
years of education (rho = 0.20, P < 0.05). The VAS HUs had a
positive correlation with income (rho = 0.21, P < 0.05) and a
negative correlation with years since HIV diagnosis (rho = -0.31,
P < 0.01). The SG had a negative relationship with years since
HIV diagnosis (rho = -0.20, P < 0.05).
Multivariate Linear Regression Models of HUs
The multiple regression models using Enter procedure showed
that generic and disease-speciﬁc health status measured with
WHOQOL-BREF THAI and frequency of HIV-related symp-
toms, and patient characteristics could explain approximately
50% of the variations in the VAS and the EQ-5D. The SG was
squared to approximate normality, and this set of predictor vari-
ables explained only 20% of the variation in the SG square
(Table 7). Signiﬁcant predictors of the VAS included physical
domain (P = 0.013), psychological domain (P = 0.012), fre-
quency of HIV symptoms (P = 0.029), and years since HIV diag-
nosis (P = 0.049). Frequency of HIV symptoms (P < 0.001) and
income (P = 0.005) were signiﬁcantly associated with the
EQ-5D. For the SG square, the psychological domain (P = 0.013)
and years since HIV diagnosis (P = 0.030) were signiﬁcant
predictors.
Feasibility
All HIV/AIDS patients who met with the investigator accepted
the interviews of VAS and EQ-5D (refusal rate = 0%). Only one
patient (0.8%) refused to be interviewed with SG. No missing
data or incomplete responses were found with all three HU
methods. Some might misunderstand that all nine SG scores of
zero were missing data or incomplete responses but they were







































Figure 1 Distribution of health utility scores: visual analog scale (VAS),
EuroQOL (EQ-5D), and standard gamble (SG) scores.
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score of zero had the mean psychological domain score of
WHOQOL-BREF THAI (12.7) lower than those of the whole
sample (14.0) and the average years since HIV diagnosis (7.3)
longer than those of the whole sample (5.2). These two variables
were signiﬁcant predictors of the SG scores. How a zero score of
SG came about was also described in the SG instrument section.
Among the three HU methods, the SG required the longest
interview time (mean = 5.2  2.4 minutes), whereas the times of
the VAS (mean = 0.9  0.3 minutes) and the EQ-5D (mean =
1.1  0.4 minutes) did not signiﬁcantly differ (t-tests, P = 0.43).
The interview times for VAS, EQ-5D and SG were independent of
age, sex, and order of interview of HU methods (P > 0.05, all).
Years of education were negatively associated with the interview
time for EQ-5D (rho = -0.27, P < 0.01) and SG (rho = -0.20,
P < 0.05). The mean scores of ease of understanding were
4.15  0.67, 4.03  0.64, and 3.68  0.67 for the EQ-5D, VAS,
and SG, respectively (the higher score indicates the less difﬁcult
method). Chi-square tests showed the SG method was more
difﬁcult to be understood than theVAS (P = 0.002) and the EQ-5D
(P < 0.001), but there was no difference in ratings of ease of
understanding between the VAS and the EQ-5D (P = 0.39). Age
and order of interview of HU methods were not associated with
the ratings of ease of understanding HU methods (all, P > 0.05).
Female patients rated VAS more difﬁcult than male patients
(chi-square test, P = 0.036), and patients with higher education
were more likely to understand the SG method than those with
lower education (rho = 0.28, P < 0.01). Badia et al. [23] found
that time of administration and ratings of difﬁculty of VAS and
TTOmethodswas independent of sex and order of administration
but signiﬁcantly correlated with age and education (P < 0.05).
Discussion
This study is the ﬁrst study to report HU in Thai patients with
HIV/AIDS measured by VAS, EQ-5D, and SG. The mean HU
scores were as follows: VAS, 0.79 (95% CI 0.76, 0.82); EQ-5D,
0.80 (95% CI 0.77, 0.84); and SG, 0.65 (95% CI 0.60, 0.70).
These values mean that the HIV/AIDS patients rated their current
health at approximately 80% of perfect health by both VAS and
EQ-5D, and were willing to undertake 35% risk of death to be
cured from HIV infection. Thai HIV/AIDS patients’ HU values
are comparable with those of other medical conditions as
follows: 0.79 (VAS) for end-stage renal disease on continuous
ambulatory peritoneal dialysis [24]; 0.78 (EQ-5D) for myocar-
dial infarction with Canadian Cardiovascular Society Functional
Classiﬁcation for Angina Pectoris Class I [25]; and 0.67 (SG) for
acute depression after 1 month of taking Imipramine [26].
The meta-analysis study of Tengs and Lin [20] found that for
HIV/AIDS patients TTO produced the highest scores, followed by
SG and VAS. SG scores were usually greater than TTO scores
which in turn were greater than VAS scores [27–29]. In contrast,
this study reported the SG scores yielded lower HU scores than
VAS and EQ-5D whose scoring function was based on TTO. A
possible explanation is that the probability of treatment effective-
ness (gamble) of the SG procedure was presented in descending
order by a 5% from a 100%chance of cure or a 0% risk of causing
death (utility = 1.0), thus lowering SG scores too much.
It is also interesting that Thai patients with HIV/AIDS rated
VAS scores higher than VAS scores derived from the study of
Tengs and Lin. There are some possible reasons for this, for
example, a rating task can depend on a subject’s numeracy or
quantitative reasoning skills [30]. If the patients had little expe-
rience with rating their health in relation to numbers, they may
Table 2 Score distributions of the HU methods
n Mean 95% CI Median Range Floor (%) Ceiling (%)
VAS 120 0.79 0.76–0.82 0.80 0.40–1.00 0.0 10.8
EQ-5D 120 0.80 0.77–0.84 0.80 0.09–1.00 0.0 28.3
SG 119 0.65 0.60–0.70 0.72 0.00–1.00 7.6 0.8
Post hoc Bonferonni comparison found that SG was signiﬁcantly lower than VAS and EQ-5D (P < 0.001, both), whereas VAS and EQ-5D did not signiﬁcantly differ (P > 0.05).
CI, conﬁdence interval; EQ-5D, EuroQol; HU, health utility; SG, standard gamble;VAS, visual analog scale.
Table 3 Comparison of HU scores of this study with those of Tengs
and Lin’s study
HU scores of this study by CD4 categories
HU methods CD4 500 200 CD4 < 500 CD4 < 200
EQ-5D 0.90 0.82 0.80
VAS 0.83 0.82 0.76
SG 0.72 0.67 0.65
HU estimates of Tengs and Lin’s study by clinical categories
HU methods Asymptomatic HIV Symptomatic HIV AIDS
TTO 0.94 0.82 0.70
VAS 0.82 0.70 0.58
SG 0.84 0.72 0.60
EQ-5D, EuroQol; HU, health utility; SG, standard gamble; TTO, time trade-off; VAS, visual
analog scale.
Table 4 Score distributions of WHOQOL-BREF THAI and HIV-related symptoms
n Mean 95% CI Median Range Floor (%) Ceiling (%) Alpha
WHOQOL-BREF THAI
PHY 120 13.9 13.8–14.4 14.3 6.9–19.4 0.0 0.0 0.73
PSY 119 14.0 13.5–14.5 14.0 5.3–20.0 0.0 1.7 0.81
SOC 116 12.9 12.4–13.4 13.3 5.3–18.7 0.0 0.0 0.61
ENV 120 13.1 12.7–13.4 13.0 7.5–19.0 0.0 0.0 0.72
HIV-related symptoms
FRE 120 7.7 6.6–8.8 6.0 0.0–28.0 3.3 0.0 0.76
Alpha, Cronbach’s alpha; CI, conﬁdence interval; ENV, environment domain; FRE, frequency of HIV symptoms; PHY, physical domain; PSY, psychological domain; SOC, social domain;
WHOQOL-BREF THAI,Thai abbreviated version of the World Health Organization quality of life.
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poorly perform rating tasks like VAS. Another possible explana-
tion is social desirability. In this study, because face-to-face inter-
views were conducted, some patients with HIV/AIDS may have
been inﬂuenced to increase their ratings in an attempt to appear
more healthy or normal.
VAS and EQ-5D agreed with each other more than with SG,
implying that SG arises from different constructs than VAS and
EQ-5D. This ﬁnding is consistent with many studies that have
shown only a weak relationship between VAS and SG values
[31–36]. Moreover, the construct validity of the SG was not
supported by relationships with health-status and disease-speciﬁc
measures, whereas the VAS [31,34–39] and EQ-5D did have such
relationships [40–44]. Our multiple regression models showed
that generic and disease-speciﬁc health status measured with the
WHOQOL-BREF THAI and frequency of HIV-related symp-
toms, and patient characteristics were able to explain only a
small part of the variation in the SG2 (adjusted R2 ~20%). In
contrast, they did play an important role in predicting HU values
measured with VAS and EQ-5D (adjusted R2 ~50% for both).
Thus, it seems that the EQ-5D and the VAS evaluated the health
of patients, but the SG valued something other than health. This
result was consistent with other studies ﬁnding that HIV patients
value their life, not their health during utility assessment [45] and
no more than 40% of the variance in utilities is explained by
patients’ HRQOL [46]. Only mental health makes substantial
contribution to utilities [47]. This was also comparable with our
result showing that psychological domain was the main predictor
of the SG. It should be noted that based on utility theory [6] only
SG is the real utility approach but VAS and EQ-5D are not.
Acceptability of all three HU approaches was quite satisfac-
tory. The elicitation methods of this study, however, were based
on face-to-face interviews. If self-administration had been
employed, the investigators believe the results could have been
quite different. From the authors’ perspective, only the VAS and
EQ-5D could have been self-administrated. Nevertheless, the
self-administration should be used for people whose education
levels are at least at the high school level. Some studies have
shown that a self-administered pencil-and-paper SG could be
reliably self-assessed [48,49]. Thus, it may be possible to create a
self-administered form of the SG questionnaire for Thai people,
if the respondents were generally well educated (e.g., college
graduates).
Conclusions
This study found that VAS, EQ-5D, and SG methods resulted in
substantially different HU values for a sample of Thai HIV/AIDS
patients. If these HU values are applied to compute QALYs for
CUA, they will greatly affect the results. Thus, sensitivity analyses
are required. VAS and EQ-5D, however, provided closer HU
scores and better agreement with each other than with SG. It is
more likely that VAS and EQ-5D will be interchangeably
employed. VAS and EQ-5D, moreover, showed evidence of stron-
ger construct validity with generic and disease-speciﬁc health
status measures, and patient characteristics than SG. Among the
three HU methods, the SG was the most difﬁcult and time-
consuming task. It needs to be administered during a face-to-face
interview. Overall, it is quite evident that VAS and EQ-5D are the
HUmethods that should be used for Thai people. The problems of
ceiling effects for both VAS and EQ-5D, however, can reduce their
value. If this is the case, SG can be an alternative HU method.
More research on the performance of these HU methods for Thai
people are needed.
Table 5 Spearman’s rank correlations between HU and HRQOL
EQ-5D VAS SG
WHOQOL-BREF
PHY 0.60* 0.54* 0.33*
PSY 0.45* 0.51* 0.34*
ENV 0.31* 0.36* 0.09
SOC 0.35* 0.37* 0.13
HIV symptoms
FRE -0.66* -0.51* -0.26*
*Correlation is signiﬁcant at the 0.01 level (2-tailed).
ENV, environment domain; FRE, frequency of HIV symptoms; HU, health utility; PHY, physical
domain; PSY, psychological domain; SOC, social domain;WHOQOL-BREF THAI,Thai abbre-
viated version of the World Health Organization quality of life.
Table 6 Spearman’s rank correlations between health utility and
patients’ characteristics
EQ-5D VAS SG
Age (continuous variable) 0.11 0.01 0.14
Sex (0 =male, 1 = female)* -0.040 -0.036 0.065
Number of years of education
(continuous variable)
0.20† 0.03 0.09
Income (continuous variable) 0.35‡ 0.21† 0.17




†Correlation is signiﬁcant at the 0.05 level (two-tailed).
‡Correlation is signiﬁcant at the 0.01 level (two-tailed).
EQ-5D, EuroQol; SG, standard gamble;VAS, visual analog scale.
Table 7 Multivariate linear regression models of HUs
Predictors
VAS EQ-5D SG2*
b P-value b P-value b P-value
Physical 0.291 0.013 0.040 0.727 0.214 0.138
Psychological 0.271 0.012 0.030 0.775 0.335 0.013
Environmental 0.043 0.665 0.124 0.202 -0.168 0.171
Social -0.008 0.931 0.127 0.191 -0.152 0.211
HIV symptoms -0.217 0.029 -0.509 <0.001 0.026 0.831
Age -0.003 0.969 -0.010 0.893 0.121 0.191
Sex -0.003 0.966 0.020 0.783 0.106 0.259
Years of education -0.039 0.625 -0.021 0.792 0.090 0.360
Income -0.145 0.064 0.221 0.005 0.119 0.218
Years since HIV diagnosis -0.147 0.049 0.056 0.444 -0.203 0.030
Adjusted R2 0.464 <0.001 0.476 <0.001 0.181 0.001
*The SG was squared to approximate normality.
EQ-5D, EuroQol; HU, health utility; SG, standard gamble;VAS, visual analog scale.
382 Sakthong et al.
We wish to thank the patients with HIV/AIDS who provided valuable
information. Dr. Sakthong conducted this research as part of her disser-
tation work at University of Minnesota.
Source of ﬁnancial support: During her graduate studies, Dr. Sakthong was
funded through the University of Minnesota Melendy Scholarship
program, the University of Minnesota Managed Care Pharmaceutical
Outcomes Fellowship program, and the Thai Government Scholar
program.
Supporting information for this article can be found at: http://
www.ispor.org/publications/value/ViHsupplementary.asp
References
1 Epidemiology Department, Ministry of Public Health. AIDS situ-
ations. Thailand, 2006. Available from: http://epid.moph.go.th
[Accessed March 14, 2007].
2 Coons SJ, Kaplan RM. Cost-utility analysis. In: Bottman JL,
Townsend RJ, McGhan WF, eds. Principle of Pharmacoeconom-
ics (2nd ed.). Cincinnati, OH: Harvey Whitney Books Company,
1996.
3 Cramer J, Spilker B. Quality of Life and Pharmacoeconomics: an
Introduction. Philadelphia: Lippincott-Raven Publishers, 1998.
4 Gold MR, Russell LB, Siegel JE, Weinstein MC. Cost-
Effectiveness in Health and Medicine. New York: Oxford Univer-
sity Press, 1996.
5 Drummond ME, Sculpher MJ, Torrance GW, et al. Methods for
the Economic Evaluation of Health Care Programmes (3rd ed.).
New York: Oxford University Press, 2005.
6 Von Neumann J, Morgenstern O. Theory of Games and Eco-
nomic Behavior. Princeton, NJ: Princeton University Press, 1944.
7 Arnsen TM, Norheim OF. Quantifying quality of life for eco-
nomic analysis: time out for time trade off. J Med Ethics 2003;29:
81–6.
8 Tsevat J, Dawson NV, Wu AW, et al. Health values of hospital-
ized patients 80 years or older: HELP investigators: Hospitalized
Elderly Longitudinal Project. JAMA 1998;279:371–5.
9 Center of Disease Control. Revised classiﬁcation system for HIV
infection and expanded surveillance case deﬁnition for AIDS
among adolescents and adults. MMWR Recom Rep 1993;41
(no.RR-17).
10 WHOQOL Group. The World Health Organization Quality of
Life assessment instrument (WHOQOL): development and
general psychometric properties. Soc Sci Med 1998;46:1569–
85.
11 WHOQOL Group. Development of the World Health Organiza-
tion WHOQOL-BREF quality of life assessment. Psychol Med
1998;28:551–8.
12 Mahatnirunkul S, Tuntipivatanakul W, Pumpisanchai W, et al.
Comparison of the WHOQOL-100 and the WHOQOL-BREF
(26 items). J Ment Health Thai 1998;5:4–15.
13 Sakthong P, Schommer JC, Gross CR, et al. Psychometric prop-
erties of WHOQOL-BREF-THAI in Patients with HIV/AIDS. J
Med Assoc Thai 2007;90:2449–60.
14 Cleary PD, Fowler FJ, Weisman J, et al. Health-related quality of
life in persons with acquired immune deﬁciency syndrome. Med
Care 1993;31:569–80.
15 Cunningham WE, Bozzette SA, Hays RD, et al. Comparison of
health-related quality of life in clinical trial and nonclinical trial
human immunodeﬁciency virus-infected cohorts. Med Care
1995;33:AS15–25.
16 Whalen CC, Antam M, Carey J, et al. An index of symptoms for
infection with human immunodeﬁciency virus: reliability and
validity. J Clin Epidemiol 1994;47:537–46.
17 Dolan P, Gudex C, Kind P, Williams A. A social tariff for
EuroQOL: results from a UK general population survey. Discus-
sion Paper No. 138, Center for Health Economics, University of
York, York, 1995.
18 Dolan P, Gudex C, Kind P. The time trade-off method: results
from a general population study. Health Econ 1996;5:141–54.
19 Torrance GW. Measurement of health state utilities for economic
appraisal. J Health Econ 1986;5:1–30.
20 Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/
AIDS. Med Decis Making 2002;22:475–81.
21 Fang CT, Hsiung PC, Yu CF, et al. Validation of the World
Health Organization quality of life instrument in patients with
HIV infection. Qual Life Res 2002;11:753–62.
22 Nunnally JC Jr. Psychometric Theory (2nd ed.). New York:
McGraw-Hill, 1978.
23 Badia X, Monserrat S, Roset M, et al. Feasibility, validity and
test-retest reliability of scaling methods for health states: the
visual analogue scale and the time trade-off. Qual Life Res 1999;
8:303–10.
24 Churchill DN, Torrance GW, Taylor DW, et al. Measurement of
quality of life in end-stage renal disease: the time trade-off
approach. Clin Invest Med 1987;10:14–20.
25 Nowels D, McGloin J, Westfall JM, Holcomb S. Validation of the
EQ-5D quality of life instrument in patients after myocardial
infarction. Qual Life Res 2005;14:95–105.
26 Anton SF, Revicki DA. The use of decision analysis in the
pharmacoeconomic evaluation of an antidepressant: a cost-
effectiveness study of nefazedone. Psychopharmacol Bull 1995;31:
249–58.
27 Bass EB, Steinberg EP, Pitt HA, et al. Comparison of the rating
scale and the standard gamble in measuring patient preferences
for outcomes of gallstone disease. Med Decis Making 1994;14:
307–14.
28 O’Leary JF, Fairclough DL, Jankowski MK, Weeks JC. Compari-
son of time-tradeoff utilities and rating scale values of cancer
patients and their relatives: evidence for a possible plateau rela-
tionship. Med Decis Making 1995;15:132–7.
29 Read JL, Quinn RJ, Berwick DM, et al. Preferences for health
outcomes: comparison of assessment methods. Med Decis
Making 1984;4:315–29.
30 Schwartz LM, Woloshin S, Black WC, Welch HG. The role of
numeracy in understanding the beneﬁts of screening mammogra-
phy. Ann Intern Med 1997;127:966–72.
31 Lin MR, Hwang HF, Chung KP, et al. Rating scale, standard
gamble, and time trade-off for people with traumatic spinal cord
injuries. Phys Ther 2006;86:337–44.
32 Brunner HI, Maker D, Grundland B, et al. Preferences-based
measurement of health-related quality of life (HRQL) in children
with chronic musculoskeletal disorders (MSKDs). Med Decis
Making 2003;23:314–22.
33 Cunningham SJ, Hunt NP. A comparison of health state utilities
for denofacial deformity as derived from patients and members of
the general public. Eur J Orthod 2000;22:335–42.
34 Goossens MEJB, Vlaeyen JWS, Rutten-van Molken MPMH,
van der Linden SMJP. Patient utilities in chronic musculoskel-
etal pain: how useful is the standard gamble method? Pain
1998;80:365–75.
35 Juniper EF, Norman GR, Cox FM, Roberts JN. Comparison of
the standard gamble, rating scale. AQLQ and SF-36 for measur-
ing quality of life in asthma. Eur Respir J 2001;18:38–44.
36 Juniper EF, Thompson AK, Roberts JN. Can the standard gamble
and rating scale be used to measure quality of life in rhinocon-
junctivitis? Comparison with the RQLQ and SF-36. Allergy
2002;57:201–6.
37 King JT, Tsevat J, Moossy JJ, Roberts MS. Preference-based
quality of life measurement in patients with cervical spondylotic
myelopathy. Spine 2004;29:1271–80.
38 Moore AD, Clarke AE, Danoff DS, et al. Can health utility mea-
sures be used in lupus research? A comparative validation and
reliability study of 4 utility indices. J Rheumatol 1999;26:1285–
90.
39 Ohsawa I, Ishida T, Oshida Y, et al. Subjective health values
of individuals with diabetes in Japan: comparison of utility
values with the SF-36 scores. Diabetes Res Clin Pract 2003;62:9–
16.
40 Delate T, Coons SJ. The use of 2 health-related quality of life
measures in a sample of persons infected with human immuno-
deﬁciency virus. Clin Infect Dis 2001;32:e47–52.
Health Utilities for HIV/AIDS in Thailand 383
41 Kaarlola A, Pettila V, Kekki P. Performance of two measures of
general health-related quality of life, the EQ-5D and the
RAND-36 among critically ill patients. Intensive Care Med 2004;
30:2245–52.
42 Luo N, Chew LH, Fong KY, et al. Validity and reliability of the
EQ-5D self-report questionnaire in English-speaking Asian
patients with rheumatic diseases in Singapore. Qual Life Res
2003;12:87–92.
43 Marra CA, Woolcott JC, Kopec JA, et al. A comparison of
generic, indirect utility measures (the HUI2, HUI3, SF-6D, and
the EQ-5D0 and disease-speciﬁc instruments (the RAQoL and
the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571–
82.
44 Wu AW, Jacobson DL, Frick KD, et al. Validity and responsive-
ness of the EuroQOL as a measure of the health-related quality of
life in people enrolled in an AIDS clinical trial. Qual Life Res
2002;11:273–82.
45 Tsevat J, Sherman SN, McElwee JA, et al. The will to live among
HIV-infected patients. Ann Intern Med 1999;131:194–8.
46 Revicki DA, Kaplan RM. Relationship between psychometric and
utility-based approaches to the measurement of health-related
quality of life. Qual Life Res 1993;2:477–87.
47 Michalos A. Social indicators research and health-related quality
of life research. Soc Indic Res 2004;65:27–72.
48 Littenberg B, Partilo S, Licata A, Kattan MW. Paper standard
gamble: the reliability of a paper questionnaire to assess utility.
Med Decis Making 2003;23:480–8.
49 Ross PL, Littenberg B, Fearn P, et al. Paper standard gamble: a
paper-based measure of standard gamble utility for current
health. Int J Technol Assess Health Care 2003;19:135–47.
384 Sakthong et al.
